Nothing Special   »   [go: up one dir, main page]

SG11201909678PA - Process for the manufacture of vortioxetine hbr alpha-form - Google Patents

Process for the manufacture of vortioxetine hbr alpha-form

Info

Publication number
SG11201909678PA
SG11201909678PA SG11201909678PA SG11201909678PA SG 11201909678P A SG11201909678P A SG 11201909678PA SG 11201909678P A SG11201909678P A SG 11201909678PA SG 11201909678P A SG11201909678P A SG 11201909678PA
Authority
SG
Singapore
Prior art keywords
international
pct
manufacture
vortioxetine hbr
alpha
Prior art date
Application number
Other languages
English (en)
Inventor
Hans Petersen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62111030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201909678P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SG11201909678PA publication Critical patent/SG11201909678PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11201909678P 2017-04-25 2018-04-20 Process for the manufacture of vortioxetine hbr alpha-form SG11201909678PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201700264 2017-04-25
PCT/EP2018/060192 WO2018197360A1 (en) 2017-04-25 2018-04-20 Process for the manufacture of vortioxetine hbr alpha-form

Publications (1)

Publication Number Publication Date
SG11201909678PA true SG11201909678PA (en) 2019-11-28

Family

ID=62111030

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909678P SG11201909678PA (en) 2017-04-25 2018-04-20 Process for the manufacture of vortioxetine hbr alpha-form

Country Status (26)

Country Link
US (1) US11124491B2 (hr)
EP (1) EP3615518B1 (hr)
JP (1) JP7121751B2 (hr)
KR (1) KR102551433B1 (hr)
CN (1) CN110520415A (hr)
AU (1) AU2018258947C1 (hr)
BR (1) BR112018076411A2 (hr)
CA (1) CA3059515A1 (hr)
CL (1) CL2019003024A1 (hr)
CO (1) CO2019011592A2 (hr)
CY (1) CY1124974T1 (hr)
DK (1) DK3615518T3 (hr)
ES (1) ES2905962T3 (hr)
HR (1) HRP20220108T1 (hr)
HU (1) HUE057993T2 (hr)
IL (1) IL270052B2 (hr)
LT (1) LT3615518T (hr)
MA (1) MA49056A (hr)
MX (1) MX2019012765A (hr)
PL (1) PL3615518T3 (hr)
PT (1) PT3615518T (hr)
RS (1) RS62823B1 (hr)
SG (1) SG11201909678PA (hr)
SI (1) SI3615518T1 (hr)
WO (1) WO2018197360A1 (hr)
ZA (1) ZA201906829B (hr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210087155A1 (en) * 2018-02-06 2021-03-25 Piramal Enterprises Limited An improved process for the preparation of vortioxetine and salts thereof
CN112125868B (zh) * 2020-09-25 2021-08-03 中山万远新药研发有限公司 一种氢溴酸伏硫西汀晶型及其制备方法、组合物与用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
KR101627901B1 (ko) * 2006-06-16 2016-06-13 하. 룬트벡 아크티에 셀스카브 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
BR112015006075B1 (pt) 2012-09-19 2022-10-04 Sandoz Ag Composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina
EP3099669A1 (en) * 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN105367515B (zh) 2015-05-08 2017-10-27 北京北陆药业股份有限公司 一种氢溴酸沃替西汀α晶型的制备方法
CN104910099B (zh) 2015-05-22 2017-03-08 扬子江药业集团有限公司 一种氢溴酸沃替西汀晶体的制备方法
CN106316986B (zh) 2015-07-03 2019-02-05 成都弘达药业有限公司 一种1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪氢溴酸盐α型晶体的制备方法

Also Published As

Publication number Publication date
CY1124974T1 (el) 2023-01-05
IL270052A (hr) 2019-12-31
PT3615518T (pt) 2022-02-14
IL270052B2 (en) 2023-12-01
CN110520415A (zh) 2019-11-29
EP3615518B1 (en) 2021-12-15
HUE057993T2 (hu) 2022-06-28
PL3615518T3 (pl) 2022-03-07
KR20190141155A (ko) 2019-12-23
RU2019133770A3 (hr) 2021-08-27
SI3615518T1 (sl) 2022-02-28
AU2018258947A1 (en) 2019-10-31
MX2019012765A (es) 2019-12-05
LT3615518T (lt) 2022-03-10
IL270052B1 (en) 2023-08-01
BR112018076411A2 (pt) 2019-04-09
CL2019003024A1 (es) 2020-02-21
CA3059515A1 (en) 2018-11-01
AU2018258947B2 (en) 2021-02-25
WO2018197360A1 (en) 2018-11-01
EP3615518A1 (en) 2020-03-04
AU2018258947C1 (en) 2021-08-26
DK3615518T3 (da) 2022-02-07
US20200165217A1 (en) 2020-05-28
MA49056A (fr) 2020-03-04
KR102551433B1 (ko) 2023-07-04
RU2019133770A (ru) 2021-05-25
JP7121751B2 (ja) 2022-08-18
HRP20220108T1 (hr) 2022-04-15
RS62823B1 (sr) 2022-02-28
CO2019011592A2 (es) 2019-10-31
ZA201906829B (en) 2022-03-30
ES2905962T3 (es) 2022-04-12
US11124491B2 (en) 2021-09-21
JP2020517674A (ja) 2020-06-18

Similar Documents

Publication Publication Date Title
SG11201804915RA (en) Methods for treating huntington's disease
SG11201808476SA (en) Recycling of polymer matrix composite
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201808708RA (en) Heterocyclic amides useful as protein modulators
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201908456VA (en) Linker units and molecular constructs comprising same
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201901873PA (en) Tablet compositions
SG11201808992UA (en) Compositions and methods for the detection of host cell proteins
SG11201901172QA (en) A method for manufacturing a fuel component
SG11201908091QA (en) Aqueous anti-pd-l1 antibody formulation
SG11201805191SA (en) Yeast cell
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies